Category Archives: Philantropist

Clay Siegall: Scientist, Doctor, Philanthropist

Dr. Clay Siegall of Seattle Genetics is a man of many acts as he’s known in the industry as a philanthropist, investor, guest speaker, scientist, and doctor. He’s one of the co-founders to one of the most successful cancer research organizations in the world. Having so many years of experience in the game has made him a living legend (in-a-sense). The good doctor is well accomplished with a Ph.D in Genetics from George Washington University as well as a (BS) in Zoology from The University of Maryland. He also has the biggest of hearts when it comes down to helping others which has allowed him to be called a philanthropist. There just seems like there isn’t anything this guy can’t do even though he’s not a household name.

 

Leadership doesn’t come by chance and Seattle Genetics is no exception as Dr. Siegall has built a stern foundation to build on. Since it’s inception back in 1998, the company has grown dramatically over the years and as today it has well over 800 employees. Early last year Vice President Joe Biden stopped by company headquarters in Bothell, Washington for congratulatory purposes. The company’s flagship drug (ADCETRIS) is now being used in over 65 countries worldwide while it has racked up nearly $226 Million in Canada and the U.S. last year. ADCETRIS is a Antibody Drug Conjugate and it is far superior to treatments/medications of the past because of it’s effectiveness. ADCETRIS spares non-targeted cells within the body while directly delivering cell killing agents right into cancerous cells. This strategy decreases the chance of side effects for the patient which can make them feel even worse than the disease itself.

 

Dr. Clay Siegall is no fluke by any chance as he has won the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year Award as well as the 2013 University of Maryland Alumnus of the Year Award. The future looks much more promising for cancer research and Dr. Clay Siegall is steering the ship to future success.